Cyxone AB (publ), a clinical biotech company, develops disease modifying therapies for rheumatoid arthritis, multiple sclerosis, and treatments for virally induced acute respiratory disorders. Its development portfolio comprises Rabeximod in a clinical Phase II program for rheumatoid arthritis and Covid-19 infections; and T20K, a Phase 1 candidate drug for the treatment of multiple sclerosis. The company was incorporated in 2015 and is based in Malmö, Sweden.
Análisis de IA de CYXONE AB SK-,75
Haz clic en cualquier análisis a continuación para obtener información instantánea de la IA de finAgent
Últimos análisis de IA sobre CYXONE AB SK-,75
Aún no hay hilos de IA disponibles para esta empresa.